Avation Medical Company Profile

Background

Avation Medical, founded in 2016 and headquartered in Columbus, Ohio, is a neuromodulation and digital health company dedicated to making non-invasive, physiologic closed-loop neuromodulation accessible to patients across various clinical conditions. The company's flagship product, the Vivally® System, is an FDA-cleared, non-invasive, wearable neuromodulation device designed to treat urinary incontinence and urgency caused by overactive bladder (OAB) syndrome.

Key Strategic Focus

Avation Medical's strategic focus centers on developing and commercializing innovative, patient-friendly neuromodulation therapies that eliminate the need for surgery, implants, or drugs. The Vivally System exemplifies this approach by offering a non-invasive, at-home treatment for OAB, utilizing proprietary algorithms and electromyographical sensors to deliver personalized therapy. The company targets the substantial market of over 46 million individuals in the U.S. affected by OAB, aiming to provide a convenient and effective alternative to traditional treatments.

Financials and Funding

In February 2024, Avation Medical secured over $22 million in an oversubscribed Series C funding round. The round was led by new investors ShangBay Capital and Asahi Kasei, with participation from Angelini Ventures, JobsOhio Growth Capital Fund, and existing investors including Arboretum Ventures, Tonkawa, Medtronic, and Avestria Ventures. The capital is earmarked for the U.S. launch and commercialization of the Vivally System.

Pipeline Development

The Vivally System is Avation Medical's primary product, having received FDA 510(k) clearance in April 2023. Clinical trials demonstrated significant reductions in daily void, incontinence, and urgency episodes, along with improved patient quality of life. The system achieved an 88% therapy compliance rate, with symptom reduction sustained over a year, even with decreased therapy frequency. The Vivally System was launched in select U.S. markets in early Spring 2024.

Technological Platform and Innovation

Avation Medical's Vivally System stands out due to its proprietary closed-loop neuromodulation technology. The device employs electromyographical sensors and algorithms to detect and calibrate the energy delivered to the tibial nerve, ensuring optimal, customized therapeutic output in real-time. This non-invasive, at-home wearable device offers a significant advancement over traditional neuromodulation therapies that often require surgical implantation or in-office procedures.

Leadership Team

Jason Whiting: Appointed Chief Executive Officer in November 2024, Jason brings over 25 years of experience in the medical technology industry, including leadership roles at ZOLL Cardiac Management Solutions.

Manish Vaishya, PhD, MBA: Co-Founder and Chief Technology Officer, Manish has a robust background in medical technology and digital health, driving the development of Avation's innovative neuromodulation therapies.

Jackie Gerberry, CPA, MBA: Vice President of Finance and Human Resources, Jackie oversees financial operations and human resources, contributing to the company's strategic growth.

Leadership Changes

In November 2024, Jason Whiting succeeded Jill Schiaparelli as CEO. Jason's extensive experience in bringing wearable technologies to market is expected to accelerate Avation Medical's growth and profitability.

Competitor Profile

Market Insights and Dynamics

The global market for non-invasive medical devices was valued at approximately $44.7 billion in 2021 and is projected to reach $90.4 billion by 2028, growing at a CAGR of 10.9%. The wearable health technology market is projected to grow from $87 billion in 2020 to $265 billion by 2026, representing a CAGR of 21.3%. This surge reflects a heightened consumer interest in personal health management.

Competitor Analysis

Avation Medical faces competition from established medical device companies such as Medtronic, Boston Scientific, and Abbott Laboratories. Medtronic reported a revenue of $30.12 billion in fiscal year 2022, holding a substantial market share in the medical device sector. Boston Scientific's revenue for the same period was $11.9 billion, while Abbott's revenue reached $43.07 billion. These companies have significant resources and established customer bases, posing competitive challenges to Avation Medical.

Strategic Collaborations and Partnerships

Avation Medical has established strategic partnerships with over 30 leading healthcare institutions and hospitals across the United States. These collaborations enhance product validation, clinical trials, and distribution, promoting the adoption of their technologies among both healthcare providers and patients.

Operational Insights

Avation Medical's focus on non-invasive, patient-friendly neuromodulation therapies positions it uniquely in the market. The Vivally System's at-home usability and closed-loop technology offer distinct advantages over traditional, more invasive treatments. However, the company must navigate challenges such as high development and production costs, regulatory hurdles, and competition from established players with significant market share.

Strategic Opportunities and Future Directions

The growing demand for non-invasive medical treatments and the expansion into emerging markets with increasing healthcare needs present significant opportunities for Avation Medical. Collaborations with tech companies for integration with digital health platforms and increasing consumer interest in personal health monitoring devices further enhance the company's growth prospects. Leveraging telemedicine trends can also provide wider reach and accessibility for patients.